Richmond Research Institute is proud to have been invited to become a member of the Foundation for the National Institutes of Health’s Biomarkers Consortium (BC). This strategic partnership signifies Richmond Research Institute's commitment to advancing healthcare innovation through collaborative efforts in the development of biomarkers to provide patients and clinicians with meaningful measures of diagnosis and progression of disease.
By joining the FNIH Biomarkers Consortium, Richmond Research Institute aims to contribute significantly to the development of clinically relevant biomarkers, fostering advancements in therapeutic development and health technologies. This strategic collaboration aligns with our dedication to pushing the boundaries of medical research and underscores our commitment to improving patient outcomes.
James Rickard, Chief Scientific Officer at Richmond Research Institute, stated, "Being invited to join the FNIH Biomarkers Consortium reflects our commitment to collaborative, impactful and innovative research. We look forward to contributing our scientific expertise in metabolic and cardiovascular disease to drive progress in patient care."
The Biomarkers Consortium, a flagship initiative of the Foundation for the National Institutes of Health (FNIH), is driven by core principles that bridge the gap between basic research and practical needs for advancing drug development and regulatory science. All BC projects operate in a pre-competitive space, with results released to the public at the earliest opportunity. Projects are collaboratively developed with contributions from academia, government, third sector and industry stakeholders, spanning various therapeutic areas.
About the FNIH Biomarkers Consortium
The Biomarkers Consortium, a flagship initiative of the Foundation for the National Institutes of Health (FNIH), spearheads cross-sector initiatives aimed at validating and qualifying biomarkers. These efforts play a crucial role in expediting the development of new therapeutics and health technologies. The BC's operations are underpinned by its contributing membership program, which includes esteemed entities such as the National Institutes of Health, the U.S. Food and Drug Administration, private industry, and not-for-profit organizations.
Since its founding in 2006, the Biomarkers Consortium has successfully approved and initiated over 35 projects. This rich history of collaborative initiatives has significantly contributed to advancing medical research, transforming the landscape of drug development, and addressing critical health challenges.
About the Foundation for the National Institutes of Health
The Foundation for the National Institutes of Health (FNIH) orchestrates public-private partnerships that connect leading biomedical scientists at the National Institutes of Health (NIH), life sciences companies, foundations, academia, and regulatory agencies, including the Food and Drug Administration and European Medicines Agency. Through collaborative team science, the FNIH tackles complex health challenges, accelerates breakthroughs for patients, and promotes global health and equity in care. Established by Congress in 1990 to support the NIH's mission, the FNIH operates as a not-for-profit 501(c)(3) charitable organization.
.svg)
